- Global Pharma News & Resources

Contrast Media Injectors Market is expected to reach US$ 2.4 Bn by 2030

[269 pages Report] FMI, an ESOMAR-certified market research firm, estimates global contrast media injectors market revenues to reach US$ 1.5 Bn in 2022. In its new study, FMI takes a long-term optimistic view of the market, estimating global revenues to grow at 6.2% CAGR through 2030. The report opines that AI’s growing penetration in the healthcare sector will also rub off on contrast media injectors industry during the next decade.

Data Points Market Insights
Market Value 2021 USD 1.4 Bn
Market Value 2022 USD 1.5 Bn
Market Value 2030 USD 2.4 Bn
CAGR 2022-2030 6.2%
Key Players The key players are Bayer AG, Nemoto Kyorindo Co. Ltd., Mallinckrodt, Bracco Imaging, Ulrich GmBh, Guerbet SA, Medtron AG,
Share of Top 5 Countries 58.1%
To remain ahead of your competitors, request for a sample – Key Takeaways of Contrast Media Injectors Market Study 

  • North America is expected to be the most lucrative region and account for more than 32% of revenue in the global contrast media injectors in 2022 and this trend is expected to continue during the forecast period
  • Larger patient pool and increasing government support towards developing healthcare system in Asian countries are expected to propel the growth of the contrast media injectors market in the region
  • AI is expected to speed up the process of injecting contrast media in the forecast period
  • Increasing applications in orthopedic surgeries and neurosurgeries to bolster the market in the forecast period

“Development of advanced contrast media injectors including automated and IT/software technology at low cost is the major focus area of the manufacturers, which provides a competitive advantage” says an FMI Analyst.

New Product Launches and Approval – The Ongoing TrendThe market players are into getting their new products launched as well as approved to stay in the competition and also keep pace with the market scenario (that of continuing to innovate). The constructive steps in this regard are:

  • In Apr 2022, Guerbet announced getting approved by the US FDA for manufacturing gadoterate meglumine (Dotarem) injection inside the US. Till late 2019, this production used to happen outside of the US.
  • In Nov 2021, the US FDA approved an MRI contrast agent “Clariscan” for intravenous use in spine, brain (intracranial), and associated tissues.
  • In Aug 2021, Bracco Diagnostics, Inc. announced getting approved by the US FDA for oral suspension of barium sulfate (Varibar Thin Liquid). The basic use of this contrast agent is detection and assessment of dysphagia.

What else is in the report?Future market insights offer actionable insights and unique perspective on contrast media injectors market in its latest study, presenting historical demand assessment from 2014 – 2021 and projections from 2022–2030 based on product type (angiographic injectors, magnetic resonance imaging (MRI) injectors, computed tomography (CT) injectors), by end-user (hospital, ambulatory surgical centres, diagnostics centres) in seven key regions

Ask from Market Research Expert –

Contrast Media Injectors Market by CategoryBy Product:

  • CT Injectors
  • MRI Injectors
  • Cardio Injectors

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostics Centers

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
United Arab Emirates
For Sales Enquiries:

Editor Details

Last Updated: 14-Oct-2022